COMPANY
Clinical Phase 2
Keywords: acute coronary syndrome coronary artery disease myocardial infarction cardiovascular antibody monoclonal antibody Inflammation Psoriasis Cardiometabolic Syndrome Acute Coronary Syndromes Coronary Arterial Disease Heart Disease Myocardial Infarct Atherosclerotic Coronary Vascular Disease Orticumab
Location: Los Angeles, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 2: Focused Orticumab Research for Treating Inflammation in Coronary Arteries source ↗
- Trial start Phase 2: A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors source ↗
Upcoming milestones
- Feb 8, 2027 (ESTIMATED) · Phase 2 · Focused Orticumab Research for Treating Inflammation in Coronary Arteries · NCT06927739
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT04776629 | A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors | Phase 2 | Completed | Jun 30, 2021 | Nov 11, 2022 (actual) |
| NCT06927739 | Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Phase 2 | Recruiting | Aug 11, 2025 | Feb 8, 2027 (estimated) |
